Metastatic cancer remains a serious unmet need.
Novartis, Bristol-Myers Squibb evaluate potential metastatic colorectal cancer treatments | Biotechnology Focus | Biotechnology Focus – Leading change in Canada’s life science industry, from innovation to business
Colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.4 million new diagnoses in 2012. For the same period, approximately 694,000 d...
Join in on the conversation with Andrew Haller when you subscribe to Toronto Health.